Estrogen receptor-mediated effects of tamoxifen on human endometrial cancer cells.
Mol Cell Endocrinol
; 192(1-2): 93-104, 2002 Jun 28.
Article
in En
| MEDLINE
| ID: mdl-12088871
ABSTRACT
Tamoxifen is an estrogen receptor (ER)-antagonist that is widely used for the treatment of breast cancer, although it increases the risk of endometrial cancer. The mechanism mediating the stimulatory effect of tamoxifen on endometrial cancer is presently unknown. In this study we examined the effects of tamoxifen on Ishikawa 3H-12 endometrial cancer cells and MCF-7 breast cancer cells. Ishikawa cell growth was stimulated by 4-hydroxytamoxifen and accompanied by increased transcriptional activity of the endogenous ER. These stimulatory effects did not occur in MCF-7 cells. The relative transcriptional activity of the activation function (AF) 1 domain of ERalpha compared with that of the AF2 domain was 4-fold higher in Ishikawa cells than in MCF-7 cells. Mitogen-activated protein (MAP) kinase, which stimulates the transcriptional activity of AF1, was constitutively activated in Ishikawa cells, but not in MCF-7 cells. These observations suggest that the constitutively activated MAP kinase-signaling pathway in Ishikawa cells enhances the transcriptional activity of ERalpha via the AF1 domain. This ERalpha activation pathway may be involved in the stimulatory effect of tamoxifen on the development and/or progression of endometrial cancer.
Search on Google
Database:
MEDLINE
Main subject:
Tamoxifen
/
Carcinoma
/
Receptors, Estrogen
/
Gene Expression Regulation, Neoplastic
/
Endometrial Neoplasms
/
Selective Estrogen Receptor Modulators
/
Neoplasms, Hormone-Dependent
Type of study:
Prognostic_studies
Limits:
Female
/
Humans
Language:
En
Journal:
Mol Cell Endocrinol
Year:
2002
Type:
Article
Affiliation country:
Japan